ZIRCON Presentation at International Kidney Cancer Symposium 2021
Telix is pleased to release a poster on the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab), the Company’s investigational imaging agent for clear cell renal cell carcinoma (ccRCC) with positron emission tomography (PET), presented at the International Kidney Cancer Symposium (IKCS) 2021, organized by the Kidney Cancer Association.
Telix Satellite Symposium at European Association of Nuclear Medicine Annual Congress 2021
Telix is pleased to announce a satellite symposium at the 34th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held from 20-23 October 2021.
Telix at AdMeTech Summit on Precision Diagnosis and Treatment of Prostate Cancer
Telix is delighted to announce our support for the AdMeTech 5th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from 23-25 September 2021.
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
Telix is pleased to announce the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied Radiology.
Telix Symposium at SNMMI 2021 Virtual Annual Meeting
Telix is pleased to announce we will be presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Virtual Annual Meeting to be held 11 – 15 June.
Telix to Present at the 2021 Jefferies Virtual Healthcare Conference
Telix is pleased to announce that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference 2021.
Telix is pleased to announce our participation in the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting to be held 21 – 23 May 2021, live and local.